BMY Short Volume

Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry, with a market capitalization near $115.15B, listed on NYSE, employing roughly 34,100 people, carrying a beta of 0.26 to the broader market. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Led by Christopher S. Boerner, public since 1972-06-01.

Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.

Latest Date

2026-05-15

Short Volume

2.0M

Total Volume

3.1M

Short %

65.79%

30-Day Avg Short %

43.70%

Showing 30 days of FINRA short volume data for Bristol-Myers Squibb Company.

Learn how short volume is reported and how to read the data →

Frequently asked BMY short volume questions

What is the daily BMY short volume?

As of May 15, 2026, Bristol-Myers Squibb Company (BMY) short volume is 2.0M shares against 3.1M total reported volume, or 65.79% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.

How is BMY short volume reported?

FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.

What does BMY short volume tell options traders?

Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.